Eloxx Pharmaceuticals, Inc. has filed its comprehensive Annual Report on Form 10-K for the fiscal years ending December 31, 2023, 2024, and 2025, marking its first periodic filing since November 2023. The report reveals significant financial challenges, with the company reporting a net loss of $5.995 million for 2025, an increase of 91% from a loss of $3.143 million in 2024. The accumulated deficit as of December 31, 2025, stands at $300.6 million. The company has not generated any revenue from license and service agreements in 2025, following a $6.4 million revenue figure in 2024, primarily due to the termination of a collaboration agreement with Almirall, S.A. in March 2025.
Eloxx's operational expenses have decreased significantly, with total operating expenses dropping to $6.438 million in 2025 from $8.827 million in 2024, reflecting a 27% reduction. This decline is attributed to lower research and development costs, which fell to $3.056 million in 2025 from $3.577 million in 2024, and a decrease in general and administrative expenses from $5.250 million in 2024 to $3.382 million in 2025. The company anticipates continued operating losses as it focuses on advancing its lead product candidate, exaluren, which is in clinical development for rare kidney diseases, and ZKN-013, a collaboration with Almirall for rare skin diseases.
Eloxx is currently navigating a complex financial landscape, having been delisted from the Nasdaq Capital Market in October 2023 due to non-compliance with listing requirements. The company is now listed on the OTC Expert Market and is seeking to regain compliance and uplist to Nasdaq. In August 2025, Eloxx secured $15 million in funding through a securities purchase agreement with Coastlands Capital Partners LP and Domicilium, which has provided some financial relief. However, the company has expressed substantial doubt about its ability to continue as a going concern without additional funding, as its cash reserves are insufficient to maintain operations for the next twelve months.
The report outlines Eloxx's strategic focus on advancing exaluren and ZKN-013 through clinical trials, with plans to initiate a Phase 2b trial for exaluren in the first half of 2026 and a Phase 2 trial for nmADPKD in 2027. The company is also exploring additional funding options, including potential collaborations and licensing arrangements, to support its operations and product development. However, the uncertainty surrounding regulatory approvals, market conditions, and the competitive landscape poses significant risks to the company's future prospects.
About Eloxx Pharmaceuticals, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.